Amarantus Requests Rare Pediatric Disease Designation from US FDA for MANF in the Treatment of Retinitis Pigmentosa
SAN FRANCISCO, February 5, 2016 -- (Healthcare Sales & Marketing Network) -- Amarantus BioScience Holdings, Inc. (AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has... Biopharmaceuticals, Ophthalmology, FDAAmarantus Bioscience, retinitis pigmentosa
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Brain | Marketing | Neurology | Opthalmology | Pediatrics | Pharmaceuticals | Retinitis Pigmentosa